{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T06:35:19Z","timestamp":1788330919941,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001825","name":"Danish Agency for Science and Higher Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013826","name":"Candys Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005275","name":"Capital Region of Denmark","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005275","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011958","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011958","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ebiom.2023.104475","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T05:23:46Z","timestamp":1677734626000},"page":"104475","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and\/or COVID-19 vaccination"],"prefix":"10.1016","volume":"89","author":[{"given":"Alexander P.","family":"Underwood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"S\u00f8lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlota","family":"Fernandez-Antunez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe Lysemose","family":"Villadsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte S.","family":"Mikkelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrik","family":"Fahn\u00f8e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9604-4582","authenticated-orcid":false,"given":"Signe","family":"Bollerup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anni Assing","family":"Winckelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uffe Vest","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alekxander","family":"Binderup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greta","family":"Vizgirda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Louise","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline N\u00f8rl\u00f8v","family":"Vinten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus Illum","family":"Dalegaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santseharay","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Weis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7815-4806","authenticated-orcid":false,"given":"Jens","family":"Bukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2023.104475_bib1","series-title":"WHO Coronavirus Disease (COVID-19) situation\u00a0reports","author":"Organization","year":"2022"},{"issue":"10269","key":"10.1016\/j.ebiom.2023.104475_bib2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ebiom.2023.104475_bib3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"27","key":"10.1016\/j.ebiom.2023.104475_bib4","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.ebiom.2023.104475_bib5","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1056\/NEJMoa2114114","article-title":"Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar","volume":"385","author":"Chemaitelly","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104475_bib6","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/s41467-022-28936-y","article-title":"Waning of SARS-CoV-2 booster viral-load reduction effectiveness","volume":"13","author":"Levine-Tiefenbrun","year":"2022","journal-title":"Nat Commun"},{"issue":"13","key":"10.1016\/j.ebiom.2023.104475_bib7","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa2118691","article-title":"Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection","volume":"386","author":"Hall","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104475_bib8","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1038\/s41467-021-25479-6","article-title":"Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum","volume":"12","author":"Bates","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2023.104475_bib9","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.chom.2022.04.014","article-title":"Neutralization of SARS-CoV-2 omicron sub-lineages BA.1, BA.1.1, and BA.2","author":"Evans","year":"2022","journal-title":"Cell Host Microbe"},{"issue":"11","key":"10.1016\/j.ebiom.2023.104475_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103341","article-title":"Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera","volume":"24","author":"Tada","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.ebiom.2023.104475_bib11","article-title":"Relative contagiousness of emerging virus variants: an analysis of the Alpha, Delta, and Omicron SARS-CoV-2 variants","author":"Hansen","year":"2021","journal-title":"Econom J"},{"issue":"7","key":"10.1016\/j.ebiom.2023.104475_bib12","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104475_bib13","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","article-title":"Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis","volume":"3","author":"Cromer","year":"2022","journal-title":"Lancet Microb"},{"issue":"5","key":"10.1016\/j.ebiom.2023.104475_bib14","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.chom.2021.03.005","article-title":"Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite","volume":"29","author":"Cerutti","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"6504","key":"10.1016\/j.ebiom.2023.104475_bib15","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1126\/science.abc5902","article-title":"Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability","volume":"369","author":"Brouwer","year":"2020","journal-title":"Science"},{"issue":"7898","key":"10.1016\/j.ebiom.2023.104475_bib16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104475_bib17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/all.15065","article-title":"In\u00a0vitro data suggest that Indian delta variant B. 1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion","volume":"77","author":"Augusto","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.ebiom.2023.104475_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2021.104765","article-title":"Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection","volume":"136","author":"Van Elslande","year":"2021","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.ebiom.2023.104475_bib19","doi-asserted-by":"crossref","first-page":"584251","DOI":"10.3389\/fmicb.2020.584251","article-title":"Anti-spike, anti-nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic individuals","volume":"11","author":"Brochot","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ebiom.2023.104475_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.04.009","article-title":"Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine","author":"Goel","year":"2022","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104475_bib21","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3390\/vaccines10030359","article-title":"Duration of SARS-CoV-2 immune responses up to six months following homologous or heterologous primary immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA vaccines","volume":"10","author":"Marking","year":"2022","journal-title":"Vaccines"},{"issue":"6","key":"10.1016\/j.ebiom.2023.104475_bib22","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.chom.2021.04.015","article-title":"Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans","volume":"29","author":"Vanshylla","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ebiom.2023.104475_bib23","first-page":"e531","article-title":"Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection","author":"Wang","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ebiom.2023.104475_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100734","article-title":"Antibody titers against SARS-CoV-2 decline, but do not disappear for several months","volume":"32","author":"Yamayoshi","year":"2021","journal-title":"eClinicalMedicine"},{"issue":"5","key":"10.1016\/j.ebiom.2023.104475_bib25","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.cell.2022.01.011","article-title":"SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses","volume":"185","author":"Walls","year":"2022","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104475_bib26","article-title":"Clinical course impacts early kinetics, magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection","volume":"3","author":"Pradenas","year":"2022","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104475_bib27","article-title":"Analysis of neutralization titers against SARS-CoV-2 in health-care workers vaccinated with prime-boost mRNA-mRNA or vector-mRNA COVID-19 vaccines","volume":"10","author":"Solund","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ebiom.2023.104475_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103519","article-title":"Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19","volume":"71","author":"Underwood","year":"2021","journal-title":"EBioMedicine"},{"issue":"7","key":"10.1016\/j.ebiom.2023.104475_bib29","doi-asserted-by":"crossref","first-page":"e0009721","DOI":"10.1128\/AAC.00097-21","article-title":"Overcoming culture restriction for SARS-CoV-2 in human cells facilitates the screening of compounds inhibiting viral replication","volume":"65","author":"Ramirez","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104475_bib30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J\u00a0Biomed Inform"},{"key":"10.1016\/j.ebiom.2023.104475_bib31","series-title":"The ASQC basic references in quality control: statistical techniques","article-title":"Volume 16: how to detect and handle outliers","author":"Iglewicz","year":"1993"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104475_bib32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13073-022-01045-7","article-title":"Introduction and transmission of SARS-CoV-2 lineage B.1.1.7, Alpha variant, in Denmark","volume":"14","author":"Michaelsen","year":"2022","journal-title":"Genome Med"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104475_bib33","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/infdis\/jiaa618","article-title":"Dynamics of neutralizing antibody titers in the months after severe acute respiratory syndrome coronavirus 2 infection","volume":"223","author":"Crawford","year":"2021","journal-title":"J\u00a0Infect Dis"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104475_bib34","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1080\/22221751.2020.1823890","article-title":"SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease","volume":"9","author":"Wang","year":"2020","journal-title":"Emerg Microb Infect"},{"issue":"20","key":"10.1016\/j.ebiom.2023.104475_bib35","doi-asserted-by":"crossref","first-page":"10383","DOI":"10.1128\/JVI.01653-15","article-title":"Murine antibody responses to cleaved soluble HIV-1 envelope trimers are highly restricted in specificity","volume":"89","author":"Hu","year":"2015","journal-title":"J\u00a0Virol"},{"issue":"6","key":"10.1016\/j.ebiom.2023.104475_bib36","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.immuni.2017.05.007","article-title":"Elicitation of robust tier 2 neutralizing antibody responses in nonhuman primates by HIV envelope trimer immunization using optimized approaches","volume":"46","author":"Pauthner","year":"2017","journal-title":"Immunity"},{"issue":"43","key":"10.1016\/j.ebiom.2023.104475_bib37","doi-asserted-by":"crossref","first-page":"E6639","DOI":"10.1073\/pnas.1606050113","article-title":"Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination","volume":"113","author":"Tam","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ebiom.2023.104475_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103761","article-title":"Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants","volume":"75","author":"Gro\u00df","year":"2022","journal-title":"EBioMedicine"},{"issue":"6584","key":"10.1016\/j.ebiom.2023.104475_bib39","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1126\/science.abn2688","article-title":"Broad anti\u2013SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1\/mRNA-1273 vaccination","volume":"375","author":"Kaku","year":"2022","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.ebiom.2023.104475_bib40","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and heterologous Covid-19 booster vaccinations","volume":"386","author":"Atmar","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2023.104475_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abn8014","article-title":"Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants","author":"Bates","year":"2022","journal-title":"Sci Immunol"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104475_bib42","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cell.2019.11.032","article-title":"Restricted clonality and limited germinal center reentry characterize memory B cell reactivation by boosting","volume":"180","author":"Mesin","year":"2020","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.ebiom.2023.104475_bib43","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1002\/jmv.27697","article-title":"Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: a systematic review","volume":"94","author":"Chenchula","year":"2022","journal-title":"J\u00a0Med Virol"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104475_bib44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41392-022-00980-6","article-title":"Spike protein of SARS-CoV-2 Omicron (B.1.1.529) variant have a reduced ability to induce the immune response","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ebiom.2023.104475_bib45","article-title":"Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by parental mRNA vaccine or a BA.5-bivalent booster","author":"Kurhade","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2023.104475_bib46","article-title":"Disease severity, fever, age, and sex correlate with SARS-CoV-2 neutralizing antibody responses","volume":"11","author":"Schlickeiser","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104475_bib47","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00275-21","article-title":"Sex disparities and neutralizing-antibody durability to SARS-CoV-2 infection in convalescent individuals","volume":"6","author":"Markmann","year":"2021","journal-title":"mSphere"},{"issue":"11","key":"10.1016\/j.ebiom.2023.104475_bib48","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1172\/JCI142004","article-title":"Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population","volume":"130","author":"Klein","year":"2020","journal-title":"J\u00a0Clin Invest"},{"issue":"7872","key":"10.1016\/j.ebiom.2023.104475_bib49","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41586-021-03739-1","article-title":"Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2","volume":"596","author":"Collier","year":"2021","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ebiom.2023.104475_bib50","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/s41564-021-00947-3","article-title":"Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom","volume":"6","author":"Wei","year":"2021","journal-title":"Nat Microbiol"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104475_bib51","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1038\/s41467-021-22351-5","article-title":"Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany","volume":"12","author":"Aziz","year":"2021","journal-title":"Nat Commun"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396423000403?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396423000403?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:22:17Z","timestamp":1762456937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396423000403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":51,"alternative-id":["S2352396423000403"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2023.104475","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Durability and breadth of neutralisation following multiple antigen exposures to SARS-CoV-2 infection and\/or COVID-19 vaccination","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2023.104475","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104475"}}